Will the FDA approve MAIA Biotechnology's THIO-101 for the treatment of advanced Non-Small Cell Lung Cancer by Jan 2030?
Health & MedicineOne-Off3y
Manifold MarketsNo KYCVerified resolution dataWell calibratedCurrent community forecastYes 84.3%
Forecasters
3
Question type
binary
Methodology
Play-money forecasting platform
Source type
Forecast
Market data
Updated 53 minutes ago
LaggingOct 26, 23, 3:15 AM UTCJan 2, 30, 7:59 AM UTC
Trends
Rules
1: The market resolves as "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for THIO-101 as a treatment for advanced Non-Small Cell Lung Cancer by the specified date.
- 2: The market resolves as "No" if the FDA explicitly rejects the application for THIO-101 for the mentioned indication by the specified date.
- 3: If neither approval nor rejection is announced by the FDA by the specified date, the market will resolve as "No."
- Context: https://www.businesswire.com/news/home/20231024406334/en/
- [link preview]
